// App-Quantinova.ai

: Combination Cancer Immunotherapy Targeting TNFR2 and PD-1/PD-L1 Signaling Reduces Immunosuppressive Effects in the Microenvironment of Pancreatic Tumors

Researchers

Presenter

  • X. zhang

Principal Investigators

  • M. Lao

  • Y. Duan

  • J. Xu

  • H. Yang

  • H. Ying

  • K. Sun

  • X. Bai

  • T. Liang

Medical Centers

  • The First Affiliated Hospital, School of Medicine, Zhejiang University, Department of Hepatobiliary and Pancreatic Surgery, Hangzhou, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Microphthalmia, syndromic, 9

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • TNF Receptor Superfamily Member 1B

  • Tumor necrosis factor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved